Metastatic pleural tumor is a tumor formation that arises in the pleura, which is a thin membrane that envelops the lungs. This form of the disease most often occurs as a result of metastasis of a primary tumor located in other organs, such as the lungs, breast, kidney cancer, or colorectal cancer. The main mechanism of formation of metastatic tumors in the pleura involves hematogenous or lymphogenous spread of tumor cells, which leads to the formation of secondary tumor foci. The main clinical manifestations of metastatic pleural tumor are pleurisy, dyspnea, chest pain, and systemic symptoms such as weight loss and weakness. Given the diversity of primary tumors and the reactive processes that occur in the pleura, metastatic pleural tumor requires a comprehensive approach to diagnosis and treatment.
History of the disease and interesting historical facts
The history of the study of metastatic pleural tumors dates back to classical times, when ancient physicians first noticed the connection between tumors and pleurisy. In the 19th century, the studies of S. Cottle and R. Bigelow laid the foundation for understanding metastasis. This became a powerful impetus for further clinical and experimental research in the field of oncology. Particularly significant was the discovery in 1921 by the German pathologist Gustav Röchl, who described metastatic pleurisy as a result of the spread of cancer cells from primary foci. In the early 20th century, diagnostic and treatment methods began to actively develop, including radiography and surgical procedures, which significantly changed the approach to the treatment of metastatic tumors in the pleura.
Epidemiology
Metastatic pleural tumor is relatively common among patients with other cancers. According to the National Cancer Institute, metastatic pleural lesions account for approximately 10% of all pleural tumors. The most common primary sources are lung cancer, breast cancer, and malignant tumors of the gastrointestinal tract. According to statistics, 50-65% patients with advanced end-stage cancer have evidence of metastatic pleural lesions. Despite advances in early diagnosis and improvements in medical care, survival from metastatic lesions remains poor worldwide, with a median survival time of 6-12 months.
Genetic predisposition to this disease
Genetic predisposition to metastatic pleural tumor is currently being studied with increasing interest. Certain mutations, such as activating mutations in the EGFR, HER2, and KRAS genes, are associated with an increased risk of developing lung cancer and other malignancies, which in turn can lead to metastatic pleural lesions. Several studies, including meta-analyses, have shown that mutations in the TP53 and Rb genes are also associated with unfavorable prognostic factors in metastatic cancer. Thus, molecular genetic studies may play a key role in more accurate diagnosis and treatment of metastatic pleural tumors.
Risk factors for the development of this disease
Risk factors for metastatic pleural tumor are usually related to the primary malignancy. These include:
- Smoking is the main risk factor for lung cancer, which directly increases the likelihood of metastatic process.
- Age – the risk of developing cancer increases with age, especially after age 50.
- Occupational exposure – Exposure to asbestos and other carcinogens may contribute to the development of lung cancer and metastasis.
- Genetic predisposition – having a family history of cancer can increase the risk of developing malignant tumors.
- Chronic lung diseases – such as chronic bronchitis or emphysema – may increase the risk of metastatic lung disease.
Diagnosis of this disease
Diagnosis of metastatic pleural tumor involves a comprehensive approach. The main symptoms that may indicate the disease are:
- Shortness of breath and cough.
- Chest pain.
- General malaise and weight loss.
Laboratory tests may include a complete blood count, biochemical tests, and pleural puncture for cytology. Radiologic tests such as chest x-ray, CT scan, and ultrasound are commonly used to visualize pleural fluid and tumors. Other diagnostic tests may include bronchoscopy and mediastinoscopy to obtain tissue samples. It is important to perform a differential diagnosis to distinguish metastatic tumor from other pleural disorders such as benign tumors and inflammatory processes.
Treatment
Treatment of metastatic pleural tumor requires an individualized approach and may involve a variety of strategies. General treatment aims to improve quality of life and reduce symptoms. Pharmacological treatment usually includes chemotherapy and targeted therapy that target specific molecules associated with the primary tumor. Surgical treatment may include pleural effusion or other decompressive procedures, especially if there is significant pleural fluid. Radiotherapy and supportive care to control symptoms and improve overall function may also be used to help patients cope.
List of medications used to treat this disease
The following groups of drugs can be used in the treatment of metastatic pleural tumor:
- Chemotherapeutic drugs: Paclitaxel, Cisplatin, Doxorubicin.
- Targeted therapy: Emlarnib, Traztuzumab.
- Pain relievers: Opioids, NSAIDs for pain control.
- Intermediate drugs: Steroids for anti-inflammatory effect.
Disease monitoring
Monitoring of patients with metastatic pleural tumor includes regular imaging studies and laboratory monitoring. Monitoring steps may include lung function, pleural fluid levels, and general assessment. The prognosis is individual and depends on the stage of the primary tumor, the patient's general health, and the response to treatment. Potential complications may include disease progression, the need for frequent interventions, and impact on quality of life.
Age-related features of the disease
Metastatic pleural tumor is most often diagnosed in middle-aged and elderly patients, but cases are also observed in younger people. In children and adolescents, metastatic pleural involvement is extremely rare, but may be associated with certain tumors, such as rhabdomyosarcoma or medulloblastoma. Older patients often have more aggressive forms of metastatic tumors due to the presence of concomitant pathology and a weakened immune system.
Questions and Answers
- What are the main symptoms of metastatic pleural tumor? The main symptoms include shortness of breath, chest pain, cough and weight loss.
- What diagnostic methods are used to detect this disease? X-ray, CT, pleural puncture and cytological examination of fluid are used for diagnosis.
- What is the main treatment for metastatic pleural tumor? Treatment includes chemotherapy, targeted therapy and, if necessary, surgery.
- What are the risk factors for developing metastatic pleural tumor? Major risk factors include smoking, age, occupational exposure, and history of malignancy.
- What is the expected course of the disease? Prognosis varies depending on the stage of the disease and response to treatment, but metastatic pleural tumors have a poor survival rate.
